Literature DB >> 28315449

Prophylactic Levetiracetam for Seizure Control After Cranioplasty: A Multicenter Prospective Controlled Study.

Shuli Liang1, Ping Ding2, Shaohui Zhang3, Junchen Zhang4, Jiwu Zhang5, Yuping Wu6.   

Abstract

OBJECTIVE: To study efficacy and safety of prophylactic levetiracetam (LEV) administration in adults undergoing cranioplasty.
METHODS: We prospectively enrolled and randomly divided 200 adults undergoing cranioplasty into 2 groups: LEV (prophylactic LEV for 24 weeks) and control (no prophylactic antiepileptic drugs). Demographic and clinical characteristics; occurrence of postoperative seizure; changes in IQ, memory quotient, and activities of daily living scores; and postoperative side effects during hospital stay were analyzed at 2-, 24-, and 48-week follow-up visits.
RESULTS: Significant differences were found between groups in both early-stage seizures in the initial 2 weeks and late-stage seizures in the 3-24 weeks after cranioplasty (P < 0.05). Postoperative seizures occurred in 17.0% in the control group and 4.1% in the LEV group 48 weeks after cranioplasty, which was found to be significant (P = 0.0020). Patients with abnormal preoperative or postoperative electroencephalography (EEG) with spikes or sharp waves presented with an increased number of postoperative seizures compared with patients with normal EEG readings at 48 weeks. Significant differences were found between patients with postoperative seizures and patients without postoperative seizures in regard to changes in IQ, memory quotient, activities of daily living, and patient satisfaction scores (P < 0.01). No significant difference was found in side effects between the 2 groups.
CONCLUSIONS: Postoperative seizure is a common complication of cranioplasty, especially in patients with preoperative or postoperative abnormal EEG with spikes or sharp waves. Prophylactic LEV administration significantly reduced postcranioplasty seizures during LEV usage and had few side effects.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Cranioplasty; Levetiracetam; Postoperative seizure; Prophylaxis

Mesh:

Substances:

Year:  2017        PMID: 28315449     DOI: 10.1016/j.wneu.2017.03.020

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  2 in total

Review 1.  Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery.

Authors:  Shuli Liang; Xing Fan; Feng Chen; Yonghong Liu; Binghui Qiu; Kai Zhang; Songtao Qi; Guojun Zhang; Jinfang Liu; Jianguo Zhang; Jun Wang; Xiu Wang; Ziyang Song; Guoming Luan; Xuejun Yang; Rongcai Jiang; Hua Zhang; Lei Wang; Yongping You; Kai Shu; Xiaojie Lu; Guoyi Gao; Bo Zhang; Jian Zhou; Hai Jin; Kaiwei Han; Yiming Li; Junji Wei; Kun Yang; Gan You; Hongming Ji; Yuwu Jiang; Yi Wang; Zhiguo Lin; Yan Li; Xuewu Liu; Jie Hu; Junming Zhu; Wenling Li; Yongxin Wang; Dezhi Kang; Hua Feng; Tinghong Liu; Xin Chen; Yawen Pan; Zhixiong Liu; Gang Li; Yunqian Li; Ming Ge; Xianming Fu; Yuping Wang; Dong Zhou; Shichuo Li; Tao Jiang; Lijun Hou; Zhen Hong
Journal:  Ther Adv Neurol Disord       Date:  2022-08-16       Impact factor: 6.430

2.  Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis.

Authors:  Taolin Fang; Eduard Valdes; Jennifer A Frontera
Journal:  Neurocrit Care       Date:  2021-07-20       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.